You are here: Industry Insights > Market News > U.S. likely to miss July 4 COVID-19 vaccine target, White House says

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

U.S. likely to miss July 4 COVID-19 vaccine target, White House says

firstwordpharmaJune 23, 2021

Tag: COVID-19 , Vaccine , White House

Favorites

The US will likely fail to meet President Joe Biden's goal to deliver at least one COVID-19 vaccine to 70% of adults by July 4, as reported This is Money on Tuesday.

U.S. likely to miss July 4 COVID-19 vaccine target, White House says

Officials said the administration will likely to meet the target for adults 27 and older on July 4.

"Our focus from the beginning has been continuing to redouble our efforts among demographics and groups where we need extra assistance," said White House press secretary Jen Psaki.

White House COVID-19 senior adviser Jeffrey Zients said it would probably take a few weeks beyond July 4 to meet Biden's target.

Previous:LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

Next:Biopharmaceutical CEO Brussel meeting with EU leaders focuses on equitable access to tackle COVID-19, fostering innovation and unmet needs

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

PeproMene Bio, Inc.has announced an $11M investment from the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical development of PMB-CT01 (BAFF-R CAR T cell therapy) in patients with relapsed or refractory (r/r) follicular lymphoma.

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

Macrogen and Illumina Inc. (NASDAQ: ILMN) announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.

U.S. likely to miss July 4 COVID-19 vaccine target, White House says

Related News

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Macrogen Consortium win tender for National Bio Big Data Project

You may like
More>>

U.S. likely to miss July 4 COVID-19 vaccine target, White House says

Related News

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Macrogen Consortium win tender for National Bio Big Data Project

You may likeMore>>

You may like
More>>